相关实验视频

Updated: Sep 10, 2025

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

优化肥胖管理:与GLP-1受体激动剂整合连续血糖监测

Pragati Gupta¹, Paolo Pozzilli²

¹Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Diabetes research and clinical practice

|August 23, 2025

概括

持续葡萄糖监测 (CGM) 和类似葡萄糖-1受体激动剂 (GLP-1RA) 显示出对肥胖症的治疗有希望. 它们在非糖尿病患者中的联合使用需要进一步研究以个性化代谢健康策略.

科学领域:

代谢健康和肥胖管理

背景情况:

通过持续葡萄糖监测 (CGM) 等数字工具和类似葡萄糖类-1受体激活剂 (GLP-1RA) 等药物治疗, 肥胖症的管理正在取得进展.
即使在没有糖尿病的个体中,GLP- 1 RAs,包括半胺,对于减肥和血糖控制是有效的.
CGM提供了实时的代谢洞察力,而GLP-1RA则针对高胰岛素血症和食欲调节,这表明个性化肥胖治疗的协同潜力.

研究的目的:

突出CGM和GLP-1RA在糖尿病之外的肥胖管理中的潜在协同作用.
在非糖尿病肥胖人群中结合使用这些干预措施的关键证据差距.
讨论人工智能在分析CGM数据以进行个性化治疗预测方面的未来作用.

主要方法:

关于肥胖和代谢健康的CGM和GLP-1RA现有文献的综述.
对将实时CGM数据与GLP-1RA药理效应结合的潜在益处进行分析.
探索局限性,包括缺乏随机对照试验和非标准化的CGM指标.

主要成果:

通过将实时代谢反与药物胃口和代谢调节相结合,CGM和GLP-1RA的组合提供了个性化治疗.
由于没有随机对照试验,在非糖尿病患者中评估这种综合方法,存在显著的证据差距.
目前的CGM指标缺乏肥胖管理的标准化,限制了它们的临床解释性.

结论:

协同使用CGM和GLP-1RA为治疗肥胖和打破胰岛素抵抗循环提供了一个有前途的策略.
未来的进展,特别是对CGM数据的AI驱动分析,可以优化个性化治疗反应并改善长期的代谢健康结果.
进一步的研究,包括随机对照试验,对于验证CGM和GLP-1 RA联合治疗在肥胖症中的有效性和标准化至关重要.

关键词:

持续的葡萄糖监测葡萄糖类-1受体激动剂肥胖问题

更多相关视频

Simple Continuous Glucose Monitoring in Freely Moving Mice

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...